应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GMAB Genmab A/S
盘前交易 11-18 04:49:56 EST
51.96
+0.39
+0.76%
盘前
51.38
-0.58
-1.12%
04:18 EST
最高
52.08
最低
50.86
成交量
332.24万
今开
50.90
昨收
51.57
日振幅
2.37%
总市值
325.12亿
流通市值
301.37亿
总股本
6.26亿
成交额
1.72亿
换手率
0.57%
流通股本
5.80亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|Genmab A/S盘中下跌4.09%,财报利好与癌症药突破交易热度降温
行情直击 · 11-12
异动解读|Genmab A/S盘中下跌4.09%,财报利好与癌症药突破交易热度降温
异动解读|Genmab A/S盘前下跌4.12%,前期财报利好与癌症药突破交易热度降温
行情直击 · 11-12
异动解读|Genmab A/S盘前下跌4.12%,前期财报利好与癌症药突破交易热度降温
异动解读|Genmab夜盘上涨5.68%,Q3每股收益大超预期叠加癌症药临床突破持续发酵
行情直击 · 11-10
异动解读|Genmab夜盘上涨5.68%,Q3每股收益大超预期叠加癌症药临床突破持续发酵
一家鲜为人知的生物科技公司押注癌症治疗终获重大回报:股价翻倍
老虎资讯综合 · 11-03
一家鲜为人知的生物科技公司押注癌症治疗终获重大回报:股价翻倍
抗癌药亮眼临床数据成“助推剂”!Genmab(GMAB.US)市值单周飙升逾百亿美元
智通财经 · 10-30
抗癌药亮眼临床数据成“助推剂”!Genmab(GMAB.US)市值单周飙升逾百亿美元
财报前瞻 | Genmab A/S本季度营收预计增23.03%,机构观点偏正面
财报Agent · 10-29
财报前瞻 | Genmab A/S本季度营收预计增23.03%,机构观点偏正面
美股异动 | Genmab(GMAB.US)盘中大涨近26% 股价创历史新高
智通财经 · 10-28
美股异动 | Genmab(GMAB.US)盘中大涨近26% 股价创历史新高
美股异动|抗癌新药试验报捷,生物医药股Genmab股价急升26%创历史新高
老虎资讯综合 · 10-28
美股异动|抗癌新药试验报捷,生物医药股Genmab股价急升26%创历史新高
Genmab(GMAB)盘中涨逾16% 宣布全球III期LiGeR-HN1试验获积极主要结果
金吾财讯 · 10-28
Genmab(GMAB)盘中涨逾16% 宣布全球III期LiGeR-HN1试验获积极主要结果
异动解读|Genmab A/S盘中上涨10.23%,Petosemtamab最新临床数据提振情绪
行情直击 · 10-28
异动解读|Genmab A/S盘中上涨10.23%,Petosemtamab最新临床数据提振情绪
CLDN18.2靶向ADC 3期研究达到双主要终点;双靶点ADC 3期结果积极……
同花顺 · 10-24
CLDN18.2靶向ADC 3期研究达到双主要终点;双靶点ADC 3期结果积极……
异动解读|Genmab A/S盘中上涨6.9%,卵巢癌三期试验达到主要终点
行情直击 · 10-24
异动解读|Genmab A/S盘中上涨6.9%,卵巢癌三期试验达到主要终点
异动解读|Genmab A/S盘中上涨11.11%,Rina-S卵巢癌试验缓解率达45.9%
行情直击 · 10-06
异动解读|Genmab A/S盘中上涨11.11%,Rina-S卵巢癌试验缓解率达45.9%
财报前瞻|Genmab A/S本季度营收预计增24.09%,机构观点偏正面
财报Agent · 07-30
财报前瞻|Genmab A/S本季度营收预计增24.09%,机构观点偏正面
Genmab As盘中异动 急速下挫6.75%
市场透视 · 2025-03-10
Genmab As盘中异动 急速下挫6.75%
异动解读 | Genmab业绩超预期 股价盘中大涨6.53%
异动解读 · 2025-02-14
异动解读 | Genmab业绩超预期 股价盘中大涨6.53%
【明晟公司MSCI北欧国家指数涨0.6%,报379.67点】明晟公司MSCI北欧国家指数涨0.6%,报379.67点。开发癌症抗体疗法的生物技术公司Genmab A/S涨8.5%,领跑一众成分股。最新业绩报告显示,该公司全年营收215.3亿丹麦克朗,分析师预期213.9亿克朗。
金融界 · 2025-02-14
【明晟公司MSCI北欧国家指数涨0.6%,报379.67点】明晟公司MSCI北欧国家指数涨0.6%,报379.67点。开发癌症抗体疗法的生物技术公司Genmab A/S涨8.5%,领跑一众成分股。最新业绩报告显示,该公司全年营收215.3亿丹麦克朗,分析师预期213.9亿克朗。
Genmab As盘中异动 早盘股价大涨5.03%报20.68美元
市场透视 · 2025-02-13
Genmab As盘中异动 早盘股价大涨5.03%报20.68美元
Genmab As盘中异动 早盘股价大跌7.88%
市场透视 · 2025-01-28
Genmab As盘中异动 早盘股价大跌7.88%
Genmab As盘中异动 快速拉升5.00%
市场透视 · 2025-01-22
Genmab As盘中异动 快速拉升5.00%
加载更多
公司概况
公司名称:
Genmab A/S
所属市场:
NASDAQ
上市日期:
--
主营业务:
Genmab A/S于1998年6月11日注册成立。该公司是一家国际生物技术公司,拥有一系列基于抗体的新型产品和候选产品,旨在满足癌症和其他严重疾病患者的医疗需求,并改善其治疗结果。公司建立其产品线的目标是在他们认为能够最大化其价值并对治疗领域产生有意义影响的地理区域,将药物推向市场。
发行价格:
--
{"stockData":{"symbol":"GMAB","market":"US","secType":"STK","nameCN":"Genmab A/S","latestPrice":51.96,"timestamp":1794949200000,"preClose":51.57,"halted":0,"volume":3322439,"hourTrading":{"tag":"盘前","latestPrice":51.3783,"preClose":51.96,"latestTime":"04:18 EST","volume":201,"amount":10327.378593,"timestamp":1794993498381,"change":-0.5817,"changeRate":-0.011195,"amplitude":0.000033},"delay":0,"changeRate":0.007562536358347888,"floatShares":580000000,"shares":625706800,"eps":1.169275,"marketStatus":"盘前交易","change":0.39,"latestTime":"11-18 04:49:56 EST","open":50.9,"high":52.08,"low":50.86,"amount":172029170.125903,"amplitude":0.023657,"askPrice":51.55,"askSize":500,"bidPrice":51.49,"bidSize":1400,"shortable":3,"etf":0,"ttmEps":1.169275,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795012200000},"marketStatusCode":1,"adr":0,"adrRate":0.1,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":51.96,"preHourTrading":{"tag":"盘前","latestPrice":51.3783,"preClose":51.96,"latestTime":"04:18 EST","volume":201,"amount":10327.378593,"timestamp":1794993498381,"change":-0.5817,"changeRate":-0.011195,"amplitude":0.000033},"postHourTrading":{"tag":"盘后","latestPrice":52.21,"preClose":51.96,"latestTime":"19:59 EST","volume":32211,"amount":1673800.1595,"timestamp":1794963561510,"change":0.25,"changeRate":0.004811,"amplitude":0.004811},"volumeRatio":0.8835298710666378,"impliedVol":0.5672,"impliedVolPercentile":0.572},"requestUrl":"/m/hq/s/GMAB","defaultTab":"news","newsList":[{"id":"1123916537","title":"异动解读|Genmab A/S盘中下跌4.09%,财报利好与癌症药突破交易热度降温","url":"https://stock-news.laohu8.com/highlight/detail?id=1123916537","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123916537?lang=zh_cn&edition=full","pubTime":"2026-11-12 23:15","pubTimestamp":1794496506,"startTime":"0","endTime":"0","summary":"11月12日,Genmab A/S盘中下跌4.09%,报51.555美元,成交额6614.93万美元。此次回落主要反映前期利好兑现后的交易降温。公司此前披露三季度每股收益5.51美元,显著高于市场预期的3.59美元;销售额11.87亿美元,略低于预期的11.94亿美元,并维持全年指引。同时,实验性抗癌药Petosemtamab在III期LiGeR-HN1试验中达到双重主要终点,联合帕博利珠单抗可将部分头颈癌患者死亡风险降低50%。但相关催化已推动股价前期明显重估,当前波动更多体现事件发酵后的资金分化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报亮眼却遭回调,抗癌药热度降温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137385455","title":"异动解读|Genmab A/S盘前下跌4.12%,前期财报利好与癌症药突破交易热度降温","url":"https://stock-news.laohu8.com/highlight/detail?id=1137385455","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137385455?lang=zh_cn&edition=full","pubTime":"2026-11-12 21:37","pubTimestamp":1794490638,"startTime":"0","endTime":"0","summary":"11月12日,Genmab A/S盘前下跌4.12%,报51.66美元,成交额809.92万美元。此前公司三季度每股收益5.51美元,显著高于市场预期的3.59美元;销售额11.87亿美元,略低于预期的11.94亿美元,并维持全年财务指引。同时,实验性抗癌药Petosemtamab在III期LiGeR-HN1试验中达到双重主要终点,联合帕博利珠单抗可将部分头颈癌患者死亡风险降低50%。不过,相关利好已在前期股价大幅上涨中有所反映,当前股价波动更多体现事件发酵后的交易分化。Genmab A/S于1998年6月11日注册成立。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报利好降温,Genmab盘前回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191328735","title":"异动解读|Genmab夜盘上涨5.68%,Q3每股收益大超预期叠加癌症药临床突破持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1191328735","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191328735?lang=zh_cn&edition=full","pubTime":"2026-11-10 11:39","pubTimestamp":1794281961,"startTime":"0","endTime":"0","summary":"11月10日,Genmab夜盘上涨5.68%,报58.97美元,延续近期强势表现。此次异动的消息面,主要来自公司此前披露的季度业绩与核心管线进展共振。公司第三季度每股收益为5.51美元,显著高于市场预期的3.59美元;同期销售额11.87亿美元,略低于预期的11.94亿美元。与此同时,公司实验性抗癌药Petosemtamab近期公布全球III期试验积极结果,联合帕博利珠单抗可将部分头颈癌患者死亡风险降低50%,并达到双重主要终点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报大超预期,抗癌药突破持续发酵","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158839908","title":"一家鲜为人知的生物科技公司押注癌症治疗终获重大回报:股价翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1158839908","media":"老虎资讯综合","labels":["EditorSelect"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158839908?lang=zh_cn&edition=full","pubTime":"2026-11-03 18:13","pubTimestamp":1793700806,"startTime":"0","endTime":"0","summary":"丹麦生物科技公司 Genmab 的股价在连续取得多项重大癌症药物临床试验成功后,于三个月内翻了一倍,为该公司争取更大程度地掌控自主研发和销售药物的战略注入了新的动力。这家市值约350亿美元的公司上周股价飙升48%,其中,在其试验性头颈癌治疗药物Petosemtamab公布强劲试验结果后,股价在单个交易日内大涨29%。癌症治疗领域的重大突破市场反应最为强烈的是Genmab于10月28日发布的公告。Genmab计划于11月5日公布第三季度财报。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"一家鲜为人知的生物科技公司押注癌症治疗终获重大回报:股价翻倍","news_tag":"EditorSelect","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2679429216","title":"抗癌药亮眼临床数据成“助推剂”!Genmab(GMAB.US)市值单周飙升逾百亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679429216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679429216?lang=zh_cn&edition=full","pubTime":"2026-10-30 18:26","pubTimestamp":1793355964,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,对于丹麦生物科技公司Genmab而言,本周可谓迎来了突破性时刻。数据显示,Genmab在丹麦上市的股票本周累计上涨44%,创下2008年以来最大单周涨幅,市值一周增加逾100亿美元,并将年初至今的累计涨幅扩大至近90%。与此同时,Genmab在美国上市的股票本周截至周四收盘累计上涨29%,股价于周三盘中创下59.97美元的历史新高。周三,Genmab宣布,其全球III期LiGeR-HN1临床试验取得积极的顶线结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","GMAB","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103216328","title":"财报前瞻 | Genmab A/S本季度营收预计增23.03%,机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1103216328","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103216328?lang=zh_cn&edition=full","pubTime":"2026-10-29 09:11","pubTimestamp":1793236280,"startTime":"0","endTime":"0","summary":"Genmab A/S将于2026年11月05日发布新一季财报,市场关注收入和利润走势的分化,以及高毛利授权与产品销售的结构变化。上季度公司营收11.55亿美元,同比增长24.87%,毛利率92.73%,归属于母公司股东的净利润为3.03亿美元,净利率26.23%,调整后每股收益0.49美元,同比下降9.41%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Genmab A/S本季度营收预计增23.03%,机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678666494","title":"美股异动 | Genmab(GMAB.US)盘中大涨近26% 股价创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2678666494","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678666494?lang=zh_cn&edition=full","pubTime":"2026-10-28 23:10","pubTimestamp":1793200223,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166083445","title":"美股异动|抗癌新药试验报捷,生物医药股Genmab股价急升26%创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1166083445","media":"老虎资讯综合","labels":["EditorSelect"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166083445?lang=zh_cn&edition=full","pubTime":"2026-10-28 23:04","pubTimestamp":1793199891,"startTime":"0","endTime":"0","summary":"生物科技公司Genmab(GMAB)公布旗下实验性抗癌药物Petosemtamab第三期临床试验取得正面结果,该药物联合默沙东旗下癌症免疫治疗药物,可将部分头颈癌患者的死亡风险降低50%。Genmab计划与全球各地监管机构沟通,并于未来的医学会议公布完整试验数据。受消息刺激,Genmab盘中股价急升26%,股价创历史新高。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"抗癌新药试验报捷,生物医药股Genmab股价急升26%创历史新高","news_tag":"EditorSelect","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678499675","title":"Genmab(GMAB)盘中涨逾16% 宣布全球III期LiGeR-HN1试验获积极主要结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2678499675","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678499675?lang=zh_cn&edition=full","pubTime":"2026-10-28 22:10","pubTimestamp":1793196639,"startTime":"0","endTime":"0","summary":"金吾财讯 | Genmab(GMAB)美股盘中股价大涨16.07%,最新报51.85美元,成交额3.05亿美元消息面上,GenmabA/S周三发布公告,宣布其Petosemtamab单抗III期LiGeR-HN1研究的最新数据,显示该疗法可将头颈部鳞状细胞癌患者的死亡风险降低50%。同时,客观缓解率(ORR)亦优于单用帕博利珠单抗,并达到了双重主要终点。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/Mjg1NzQ1OGJhMDJiZWVjMjcxYjFlYjJjMTY3ODIxNTA4Njc=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjg1NzQ1OGJhMDJiZWVjMjcxYjFlYjJjMTY3ODIxNTA4Njc=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307728","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128684405","title":"异动解读|Genmab A/S盘中上涨10.23%,Petosemtamab最新临床数据提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1128684405","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128684405?lang=zh_cn&edition=full","pubTime":"2026-10-28 21:43","pubTimestamp":1793194985,"startTime":"0","endTime":"0","summary":"10月28日,Genmab A/S盘中上涨10.23%,报49.235美元,成交额1.06亿美元。消息面上,公司近日披露Petosemtamab联合帕博利珠单抗用于头颈部鳞状细胞癌的Ⅱ期试验更新数据,中位总生存期达28.2个月,总缓解率63%,完全缓解率19%,中位无进展生存期为9个月,安全性可控。同时,公司还宣布与Incyte合作推进Petosemtamab在特定KRAS突变转移性结直肠癌一线治疗中的Ⅰ/Ⅱ期研究,叠加此前Rina-S在卵巢癌Ⅲ期试验达到主要终点,近期管线进展连续释放,强化市场对其后续研发价值的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Genmab大涨,头颈癌新药数据亮眼","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677276908","title":"CLDN18.2靶向ADC 3期研究达到双主要终点;双靶点ADC 3期结果积极……","url":"https://stock-news.laohu8.com/highlight/detail?id=2677276908","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677276908?lang=zh_cn&edition=full","pubTime":"2026-10-24 07:35","pubTimestamp":1792798500,"startTime":"0","endTime":"0","summary":" CLDN18.2靶向ADC国际3期研究达到双主要终点,延长胃癌患者PFS和OS 武田(Takeda)和信达生物(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tava ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261024/c681047440.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261024/c681047440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4559","LU0985481810.HKD","BK4195","GMAB","LU1670711123.USD","BK4532","BK4581","IE0009355771.USD","LU0096364046.USD","NETL","LU2596442595.SGD","BK4534","LU1032466523.USD","LU1074936037.SGD","LU0114720955.EUR","IE00BFXG1179.USD","LU1571399168.USD","LU1670711040.USD","LU0321505868.SGD","ITT","BK4139","LU1430594728.SGD","BK4585","PFS","FTXH","LU0061475181.USD","LU1670710661.SGD","IHE","LU0306806265.USD","BMY","ADC","LU1236620750.USD","LU2125154935.USD","ORR","LU0225284248.USD","LU0456855351.SGD","FFBC","LU2360032135.SGD","LU1291159041.SGD","LU0237698245.USD","LU1868837136.USD","LU0432979614.USD","IE00BSNM7G36.USD","BK4211","LU1261432733.SGD","LU2242646821.SGD","BK4231","LU1983299246.USD","IE00BFTCPJ56.SGD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170095179","title":"异动解读|Genmab A/S盘中上涨6.9%,卵巢癌三期试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1170095179","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170095179?lang=zh_cn&edition=full","pubTime":"2026-10-24 01:22","pubTimestamp":1792776145,"startTime":"0","endTime":"0","summary":"10月24日,Genmab A/S盘中上涨6.9%,报42.76美元,成交额2.98亿美元。消息面上,公司披露候选药物Rina-S在铂耐药性卵巢癌三期试验中达到无进展生存期主要终点,并达到总生存期关键次要终点,推动股价走强。数据显示,Rina-S较研究者选择化疗使总体人群疾病进展或死亡风险降低71%,主要分析集降低67%;同时使死亡风险降低57%。公司称安全性与既往结果一致,未发现新的安全问题,并计划与全球监管机构沟通后续申报事宜。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Genmab卵巢癌三期达标,股价强势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131752637","title":"异动解读|Genmab A/S盘中上涨11.11%,Rina-S卵巢癌试验缓解率达45.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131752637","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131752637?lang=zh_cn&edition=full","pubTime":"2026-10-06 03:03","pubTimestamp":1791227000,"startTime":"0","endTime":"0","summary":"10月6日,Genmab A/S盘中上涨11.11%,报38.62美元/股。消息面源于该公司公告其在铂耐药卵巢癌1/2期试验中达到45.9%确认缓解率,其中5名患者无检出癌征且中位无进展生存期9.5个月。Genmab A/S为国际生物技术公司,专注于开发基于抗体的癌症等重病疗法,目前已在新增3期试验中推进该药物。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Genmab异动拉升,卵巢癌新药缓解率亮眼","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157485485","title":"财报前瞻|Genmab A/S本季度营收预计增24.09%,机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1157485485","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157485485?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:36","pubTimestamp":1785379014,"startTime":"0","endTime":"0","summary":"Genmab A/S将于2026年08月06日发布最新财报,市场预期营收、EBIT维持同比增长,EPS或受研发与合作费用节奏影响承压。市场一致预期本季度Genmab A/S营收为11.12亿美元,同比增长24.09%;EBIT为3.50亿美元,同比增长10.42%;调整后每股收益为0.35美元,同比下降21.09%。上季度Genmab A/S营收为8.96亿美元,同比增长25.32%;毛利率为92.75%;归属于母公司股东的净利润为5,300.00万美元,净利率为5.92%;调整后每股收益为0.08美元,同比下降72.79%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|Genmab A/S本季度营收预计增24.09%,机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518271854","title":"Genmab As盘中异动 急速下挫6.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518271854?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:13","pubTimestamp":1741616005,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时13分,Genmab As股票出现异动,股价大幅下挫6.75%。Genmab As股票所在的生物技术行业中,整体涨幅为0.21%。Genmab As公司简介:Genmab AS是一家总部位于哥本哈根的生物技术公司,专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex,该药物被视为多发性骨髓瘤的标准治疗药物,是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221325abf30c0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221325abf30c0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171629140","title":"异动解读 | Genmab业绩超预期 股价盘中大涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171629140","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171629140?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:02","pubTimestamp":1739466163,"startTime":"0","endTime":"0","summary":"生物技术公司Genmab A/S(GMAB)今日盘中大涨6.53%,引发市场广泛关注。\n\n消息面上,Genmab公布2024财年业绩,全年营收215.3亿丹麦克朗,超过分析师预期的213.9亿克朗,这一良好业绩成为GMAB股价大涨的主因。\n\n公司简介显示,Genmab是一家总部位于丹麦哥本哈根的生物技术公司,专注于研发用于治疗癌症的抗体疗法。其主要产品包括治疗多发性骨髓瘤的Darzalex、治疗甲状腺眼病的Tepezza等。公司目前还拥有多个治疗其他肿瘤的候选药物在研。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Genmab业绩超预期 股价盘中大涨6.53%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511655520","title":"【明晟公司MSCI北欧国家指数涨0.6%,报379.67点】明晟公司MSCI北欧国家指数涨0.6%,报379.67点。开发癌症抗体疗法的生物技术公司Genmab A/S涨8.5%,领跑一众成分股。最新业绩报告显示,该公司全年营收215.3亿丹麦克朗,分析师预期213.9亿克朗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511655520","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511655520?lang=zh_cn&edition=full","pubTime":"2025-02-14 00:52","pubTimestamp":1739465543,"startTime":"0","endTime":"0","summary":"明晟公司MSCI北欧国家指数涨0.6%,报379.67点。开发癌症抗体疗法的生物技术公司Genmab A/S涨8.5%,领跑一众成分股。最新业绩报告显示,该公司全年营收215.3亿丹麦克朗,分析师预期213.9亿克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14005248150518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["GNMSF","GMAB","MSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511010521","title":"Genmab As盘中异动 早盘股价大涨5.03%报20.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511010521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511010521?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:29","pubTimestamp":1739460567,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时29分,Genmab As股票出现异动,股价快速拉升5.03%。截至发稿,该股报20.68美元/股,成交量68.9807万股,换手率0.11%,振幅3.25%。Genmab As股票所在的生物技术行业中,整体涨幅为0.13%。Genmab As公司简介:Genmab AS是一家总部位于哥本哈根的生物技术公司,专门从事用于治疗癌症的抗体疗法。强生公司与Genmab公司合作开发了Darzalex,该药物被视为多发性骨髓瘤的标准治疗药物,是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232927a244b7ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232927a244b7ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506148755","title":"Genmab As盘中异动 早盘股价大跌7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506148755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506148755?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:31","pubTimestamp":1738074664,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日22时31分,Genmab As股票出现异动,股价急速下跌7.88%。Genmab As股票所在的生物技术行业中,整体涨幅为0.01%。Genmab As公司简介:Genmab AS是一家总部位于哥本哈根的生物技术公司,专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex,该药物被视为多发性骨髓瘤的标准治疗药物,是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128223104abbb656c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128223104abbb656c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505478293","title":"Genmab As盘中异动 快速拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505478293","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505478293?lang=zh_cn&edition=full","pubTime":"2025-01-22 04:49","pubTimestamp":1737492596,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日04时49分,Genmab As股票出现异动,股价急速上涨5.00%。Genmab As股票所在的生物技术行业中,整体涨幅为1.76%。Genmab As公司简介:Genmab AS是一家总部位于哥本哈根的生物技术公司,专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex,该药物被视为多发性骨髓瘤的标准治疗药物,是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122044956986e737b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122044956986e737b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genmab.com","stockEarnings":[{"period":"1week","weight":-0.039},{"period":"1month","weight":0.4043},{"period":"3month","weight":0.5233},{"period":"6month","weight":0.9209},{"period":"1year","weight":0.7081},{"period":"ytd","weight":0.687}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0404},{"period":"3month","weight":-0.0476},{"period":"6month","weight":-0.0138},{"period":"1year","weight":0.1003},{"period":"ytd","weight":0.0741}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Genmab A/S于1998年6月11日注册成立。该公司是一家国际生物技术公司,拥有一系列基于抗体的新型产品和候选产品,旨在满足癌症和其他严重疾病患者的医疗需求,并改善其治疗结果。公司建立其产品线的目标是在他们认为能够最大化其价值并对治疗领域产生有意义影响的地理区域,将药物推向市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.047195},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.023242},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.023166},{"month":4,"riseRate":0.571429,"avgChangeRate":0.046297},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024549},{"month":6,"riseRate":0.571429,"avgChangeRate":0.011635},{"month":7,"riseRate":1,"avgChangeRate":0.074646},{"month":8,"riseRate":0.625,"avgChangeRate":0.058933},{"month":9,"riseRate":0.25,"avgChangeRate":-0.012715},{"month":10,"riseRate":0.5,"avgChangeRate":0.058872},{"month":11,"riseRate":0.625,"avgChangeRate":0.05095},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.017923}],"exchange":"NASDAQ","name":"Genmab A/S","nameEN":"Genmab A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Genmab A/S(GMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Genmab A/S,GMAB,Genmab A/S股票,Genmab A/S股票老虎,Genmab A/S股票老虎国际,Genmab A/S行情,Genmab A/S股票行情,Genmab A/S股价,Genmab A/S股市,Genmab A/S股票价格,Genmab A/S股票交易,Genmab A/S股票购买,Genmab A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Genmab A/S(GMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}